JAK抑制剂治疗斑秃的系统评价与荟萃分析
该系统评价与荟萃分析纳入30项研究共289例斑秃病例,评估托法替尼、鲁索替尼和巴瑞替尼的疗效。结果显示应答率72.4%,良好应答45.7%,部分应答21.4%;口服途径应答显著优于局部治疗,儿童与成人应答比例无差异。证据质量偏低,需大规模随机研究证实。
要点
- JAK抑制剂治疗斑秃总应答率72.4%,良好应答45.7%。
- 口服途径应答显著优于局部治疗,儿童与成人应答比例无差异。
- 证据质量偏低,需大规模随机对照研究进一步验证。
核心结论
- JAK抑制剂治疗斑秃显示出有前景但低质量的证据,需未来大规模随机研究确认。
研究设计与样本
- 按PRISMA指南进行的系统评价与荟萃分析,纳入30项研究共289例斑秃病例。
主要发现
- 总应答率为72.4%,良好应答为45.7%,部分应答为21.4%。
- 初始毛发生长平均时间为2.2±6.7个月,完全毛发再生时间为6.7±2.2个月。
- 全部37例复发均发生在治疗停止后2.7个月时。
- 口服途径与治疗应答显著相关,优于局部治疗。
- 儿童与成人病例的应答比例无差异。
临床怎么用
- 口服JAK抑制剂可能作为斑秃的治疗选择,但需权衡低质量证据并监测停药后复发。
局限性
- 现有文献多基于小样本数据,缺乏确定性证据或指南,证据质量低。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
There have been a number of case reports and small clinical trials reporting promising outcomes of Janus Kinase (JAK) inhibitors tofacitinib, ruxolitinib and baricitinib for alopecia areata (AA). The majority of the literature to date is based on small volume data, with a lack of definitive evidence or guidelines. To determine the expected response of AA to JAK inhibitor therapy and factors which influence response and recurrence rates. A systematic review and meta-analysis was performed according to PRISMA guidelines. From 30 studies and 289 cases, there were 72.4% responders, good responders 45.7% and partial responders 21.4%. Mean time to initial hair growth was 2.2 ± 6.7 months, and time to complete hair regrowth was 6.7 ± 2.2 months. All 37 recurrences occurred when treatment was ceased after 2.7 months. Oral route was significantly associated with response to treatment compared to topical therapy. No difference was found between paediatric and adult cases in proportion of responses. There is promising low-quality evidence regarding the effectiveness of JAK inhibitors in AA. Future large-sized randomized studies are required to confirm findings.
引用
- Phan K, Sebaratnam DF. JAK inhibitors for alopecia areata: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2019. PMID: 30762909. doi:10.1111/jdv.15489
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。